Shopping Cart
- Remove All
Your shopping cart is currently empty
AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $50 | In Stock | |
| 5 mg | $113 | In Stock | |
| 10 mg | $189 | In Stock | |
| 25 mg | $347 | In Stock | |
| 50 mg | $562 | In Stock | |
| 100 mg | $783 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $126 | In Stock |
| Description | AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM). It reduces toxic galactitol levels and prevents disease complications in GALT deficiency rats. |
| Targets&IC50 | Aldose reductase:100 pM |
| In vivo | AT-007 markedly reduces galactitol levels across all target tissues (liver, brain, and plasma) in GALT null rats, without elevating galactose or Gal-1P concentrations [2]. |
| Molecular Weight | 425.4 |
| Formula | C17H10F3N3O3S2 |
| Cas No. | 2170729-29-8 |
| Smiles | OC(=O)Cc1nn(Cc2nc3cc(ccc3s2)C(F)(F)F)c(=O)c2cscc12 |
| Relative Density. | 1.72 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 35.71 mg/mL (83.94 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.